Cannabidiol (Epidyolex) approved in the EU for the treatment of seizures associated with tuberous sclerosis complex

Approval (for use in patients aged 2 years and over) is based on data from a phase 3 safety and efficacy study evaluating 25 mg/kg/day of cannabidiol, which found a greater reduction in seizure frequency vs placebo (49% vs 27%, p=0.0009).

Source:

Biospace Inc.